Validation Study With a Non-CE Marked Medical Device (MD)

This interventional study aims to validate the cough detection device by automatically and continuously measuring the cough frequency with SIVA-MVP among chronic cough patients and in a real-world environment.

Study Overview

• Status: Completed
• Conditions: Chronic Cough
• Intervention / Treatment: Device: SIVA-MVP

Detailed Description

After chronic cough diagnosis, the Principal Investigator (or his designee) will identify potentially eligible patients to participate in this study based on the predefined inclusion criteria.

The study will recruit patients with a cough that has lasted for at least 12 months and persistent for the previous 8 weeks with a diagnosis or suspicion of refractory chronic cough, or patients with a diagnosed asthma. A total of 50 patients will be enrolled in the study.

Patients who decide to participate will be entered into the study after obtaining their informed consent. They will receive the SIVA-MVP wearable and the associated accessories. They will be asked to rate their current cough severity on a visual analog scale (Cough Severity VAS) and fill in a Leicester Cough Questionnaire (LCQ) to assess the impact of cough on their quality of life. Participants will receive a second Cough Severity VAS and LCQ to fill at the end of the study and a return envelope.

Participants will receive standard care and be asked to wear SIVA-MVP on their chest during the day and charge it on the bedside during sleep for 14 days. Every evening, they will be prompted by the SIVA-MVP smartphone application to indicate the timing of their main meals.

On day 15, the study nurse will conduct a pre-scheduled phone interview with each participant. The phone interview will include instructing the patient to fill in the final Cough Severity VAS and LCQ, asking the questions of the Participant User Feedback Questionnaire, and instructing the patient to send the questionnaire forms and the SIVA-MVP wearable and the accessories back to the trial site using the return envelope. The Participant User Feedback Questionnaire will include ratings of wearing comfort, usability, and likeliness to wear for an extended period of time.

• Study Type: Interventional
• Enrollment (Actual): 50
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Washington
    • Bellingham, Washington, United States, 98225
      • Bellingham Asthma, Allergy & Immunology Clinic

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 21 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Informed Consent as documented by signature
• Adult men and women at the date of signing the Informed Consent Form
• Patients with a diagnosis or suspicion of refractory chronic cough or patients with a diagnosed asthma
• Attending the treatment procedure as an outpatient
• Comfortable with using a smartphone and willing to use an external iPhone daily for the duration of the study.
• Adequate communication in US English (all study documentation and SIVA-MVP will be set to English language only).

Exclusion Criteria:

• Unable to make the decision to participate in a clinical study (e.g., seriously ill or unconscious subject, or subject with a mental or intellectual disability)
• Inability to follow the procedures of the study, e.g., due to physical or intellectual impairment precluding informed consent or protocol adherence, psychological disorders (excluding depression) or dementia
• Use of any other medical device equipment (e.g., portable oxygen concentrator, artificial cardiac pacemaker, implantable cardioverter-defibrillator)
• Pregnancy: Female participants in child-bearing age without a negative pregnancy test (urine test). Female participants who are neither surgically sterilized / hysterectomized nor post-menopausal for longer than 2 years are considered to be of childbearing potential.
• Known or suspected non-compliance, drug or alcohol abuse
• Participation in another clinical study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: SIVA-MVP; Wearable cough detection device with a corresponding smartphone application and charging device.

Device: SIVA-MVP; Participants receive a small, wearable data recorder, wear it during the day and charge it on the nightstand during sleep for 14x24 hours. The encrypted, recorded segments are uploaded to a server. The server provides a secure environment where the segments are decrypted after receiving the required keys from the patient's SIVA smartphone application. The decrypted segments are then classified as cough by a machine learning algorithm. Participants respond to questions on a smartphone once a day for additional context data. The audio data from the first 24 hours after the patient started wearing the device are used for the validation of the performance of the cough detection algorithm.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Performance of the SIVA-MVP cough detection device	Validation of a SIVA-MVP performance of detecting individual cough events in a target population over a 24-hour validation phase (first 24 hours after baseline visit). Sensitivity, specificity, and positive and negative predictive values contribute to a description of cough monitor performance.	First 24 hours

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Wearing comfort	Wearing Comfort will be determined through quantitative analysis of questions in the Participant User Feedback Questionnaire measured with 5-level Likert Scale (Disagree, Somewhat disagree, Neither agree nor disagree, Somewhat agree, Agree).	2 weeks
Number of potential adverse events, serious adverse events, device deficiency and serious device deficiency	Device safety measured as the number of potential adverse events, serious adverse events, device deficiency and serious device deficiency.	2 weeks
Comparison of objectively recorded (device) data and subjectively reported (patient) data measured with Leicester Cough Questionnaire and Cough Severity VAS	Correlation of patient reported outcomes measured with Leicester Cough Questionnaire and Cough Severity Visual Analog Scale (VAS) with recorded cough frequency during 14x24h.	At Baseline and at the end of 2 weeks
Wearing time	Effective wearing times per day as recorded by the device.	2 weeks
Effective reply rate	Effective reply rate of patients to questions for context information asked to them via the smartphone application	2 weeks
Cough frequency patterns	Degree of similarity between cough patterns of different days within one patient and between patients.	2 weeks

Collaborators and Investigators

• Sponsor: Siva Health AG

Study record dates

Study Major Dates

• Study Start (Actual): March 2, 2023
• Primary Completion (Actual): November 22, 2024
• Study Completion (Actual): November 22, 2024

Study Registration Dates

• First Submitted: January 6, 2023
• First Submitted That Met QC Criteria: January 16, 2023
• First Posted (Actual): January 19, 2023

Study Record Updates

• Last Update Posted (Actual): May 15, 2025
• Last Update Submitted That Met QC Criteria: May 12, 2025
• Last Verified: May 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Respiration Disorders; Signs and Symptoms, Respiratory; Cough; Chronic Cough
• Other Study ID Numbers: SIVA-VS2

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No